A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but ...

Stuart Therapeutics has reported initial findings from its 29-day randomised Phase III trial of the ST-100 (vezocolmitide) ...

Topline data were announced from a phase 3 trial evaluating ST-100 ophthalmic solution for the treatment of dry eye disease.

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate that it can increase tear production in a phase 3 test.

Researchers have found in a phase 3 trial that phentolamine ophthalmic solution 0.75% led to significant improvements in ...